Epidermal growth factor (EGF) and estradiol (E2) are important mitogens in breast epithelial cells, and expression of epidermal growth factor receptor (EGFR) and estrogen receptor (ER) is often inversely correlated in human breast cancer cells. Stable transfection of ER-negative cells with ER cDNA is not sufficient to restore E2-mediated growth stimulation, on the contrary, E2 often inhibits growth of ER-transfected cell lines. In this study we used the ER-transfected human breast epithelial cell lines HMT-3522F9, growth inhibited by E2 in the presence of EGF, and HMT-3522F9/S3B, growth stimulated by E2 in the absence of EGF. In S3B cells, no active MAP kinase could be detected in response to E2, suggesting that signalling through the MAP kinase is not the major pathway in the E2-mediated growth stimulation. Interestingly, a decreased level of active MAP kinase was observed in HMT-3522F9 cells in response to E2, indicating that in these cells cross-talk between the ER and the MAP kinase signalling pathway could be due to the E2-mediated growth inhibition. Moreover, we found that EGF-induced signalling also could be reduced by E2 in S3B cells, suggesting a general mechanism of action by E2 in cells concomitantly expressing ER and EGFR.
Introduction
Steroid hormones and polypeptide growth factors such as epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) are important regulators of both normal growth and development as well as malignant progression of the mammary gland [1, 2] . For many years it was thought that steroid hormones and polypeptide hormones were acting independently and via distinctly different mechanisms:
(1) steroid hormones interacting directly with intracellular receptors belonging to a family of liganddependent transcription factors (e.g. estrogen acting via the estrogen receptor α (ER), and (2) growth factors interacting with tyrosine kinase associated membrane receptors producing intracellular signals responsible for short-term responses.
However, estrogen-inducible polypeptide growth factors may act as autocrine and paracrine mediators of estrogen action both in normal and neoplastic breast tissues [1] , as estrogen regulates the expression of EGF, IGF-I, transforming growth factor-α (TGF-α), and their receptors [3] [4] [5] . Recently, evidence has accumulated showing that the ER may be activated in a ligand-independent manner by a variety of agents that include several polypeptide growth factors [6] [7] [8] , the neurotransmitter dopamine [9] , and cAMP [10] . Activation of estrogen-responsive genes has been shown to be stimulated by these agents by a mechanism that is inhibited by the pure antiestrogen ICI 164,384 [11] . Moreover, the estrogen-like response of EGF lacks in the uteri of ER knockout mice [12] . The molecular mechanisms for cross-talk between ER and other signalling pathways may in part be mediated by receptor phosphorylation, as it has been demonstrated that ER is phosphorylated at serine 118 (Ser118) by the mitogen activated protein kinase (MAP kinase or MAPK) pathway in response to EGF [13] . Furthermore, ER is also capable of activating the tyrosine kinase/Ras/MAP kinase pathway in MCF-7 breast cancer cells, demonstrating that crosstalk surely exists between the ER and growth factor receptor pathways [14] [15] [16] .
In normal human mammary epithelium about 7% of the epithelial cells (HMECs) express ERs [17] , whereas the fraction of cells expressing ERs in ERpositive human breast tumors is approximately 60% [18] . The marked increase in cells expressing ERs in ER-positive tumors compared to normal HMEC, together with the fact that 80% of the primary breast tumors are classified as ER-positive tumors [19] , suggest a role for estrogen in the malignant transformation. To elucidate the role of estrogen in the growth of normal mammary epithelial cells, we have stably transfected the ER-negative non-tumorigenic human mammary epithelial cell line, HMT-3522S1 [20] with the human estrogen receptor cDNA [21] . Paradoxically, the ER-positive, established cell line, HMT-3522F9 (termed F9 henceforward) was growth inhibited by estrogen, simultaneously with an estrogen up-regulation of several genes, known to be involved in estrogenstimulated cell proliferation [22] . Several laboratories have attempted to restore estrogen responsiveness by transfecting the ER cDNA into different ER-negative cell types. However, all transfection studies have resulted in a negative or no growth response to estrogen [23] . This unexpected response to estrogen is not only exhibited by non-breast cells such as 3T3 (mouse fibroblasts), CHO (Chinese hamster ovary), human osteosarcoma cells, and HeLa cells (human cervical carcinoma) but also by tumorigenic and nontumorigenic human breast epithelial cells transfected with the ER cDNA [23] .
Thus, stable transfection of ER negative cells with ER cDNA is not sufficient to restore a positive estrogen-mediated growth response. The expression of epidermal growth factor receptor (EGFR) and ER in several breast cancer cell lines are inversely correlated, and this inverse correlation between ER and EGFR is possibly disturbed in ER-transfected cell lines often expressing high levels of both ER and EGFR. Furthermore, it has been suggested that expression of these two receptors is mutually exclusive [24, 25] . These observations indicate that neither receptor function optimally when expressed concomitantly. Our observation that estradiol (E2) in F9 cells inhibits growth also supports this hypothesis. In fact, by avoiding activation of the EGFR by omitting EGF from the growth medium, we have been able to establish a F9 subline, HMT-3522F9/S3B (termed S3B henceforward), which is dependent on E2 for growth [26] . Thus, it is possible that it is a change in the expression or activation of the EGFR, which results in the E2-mediated growth differences observed in F9 and S3B cells. Hence, in the present study we looked at the different growth mechanisms of F9 and S3B cells in response to E2 in relation to the EGFR/MAP kinase signalling pathway.
Materials and methods

Cell lines and culture conditions
The parental cell line, HMT-3522S1 was propagated as monolayer culture in a chemically defined medium (H14) composed of Dulbecco's modified minimum essential medium plus Ham's F-12 (1:1), 2 mM glutamine; 250 ng/ml insulin (Novo-Nordic, Copenhagen, Denmark); 2.6 ng/ml sodium selenite (Collaborative Research, Waltham, MA, USA); 10 µg/ml transferrin (Sigma Chemical Co., St. Louis, MO, USA); 10 ng/ml EGF (Sigma) 10 −8 M 17-β-estradiol (E2) (Collaborative Research); 5 µg/ml ovine prolactin (Sigma), and 1 µM hydrocortisone (Sigma) [20] . The ERtransfected HMT-3522F9 cell line was derived by selection from a single clone and cultivated in H14 medium, without E2 and supplemented with 1% NCS (newborn calf serum) and G418 (200 µg/ml) (Gibco BRL, Life Technologies, Inc., Paisley, Scotland). For establishment of the HMT-3522F9/S3B cell line, F9 cells were adapted to grow in serum-free medium, before withdrawal of EGF. S3B cells was derived from pooled clones and were cultivated in chemically defined H14 medium without EGF, with 10 nM E2 and supplemented with G418 (200 µg/ml). The human breast cancer cell line MCF-7 [27] was obtained from The Breast Cancer Task Force Cell Culture Bank, Mason Research Institute (Worcester, MA, USA) and was propagated in Dulbecco's modified minimum essential medium plus Ham's F-12 (1 : 1) supplemented with 1% FCS (foetal calf serum), 2 mM glutamine, and 6 ng/ml insulin. MCF-7/S9 cells have been adapted to grow in Dulbecco's modified minimum essential medium plus Ham's F-12 (1 : 1) without addition of serum or growth factors [28] . All cell lines were grown in phenol red-free medium. The cell lines were passaged every week by trypsinization. Medium was changed every second or third day. The cell lines were regularly tested by the Hoechst staining method and were found free of Mycoplasma. ICI 182,780 was provided by Zeneca Pharmaceuticals, Macclesfield, UK.
Growth experiments
Cells were seeded in growth medium in 24-well dishes (2 cm 2 /well; Nunc, Roskilde, Denmark) at a density of 2 × 10 4 cells per cm 2 . Two days later (Day 0), the reagent of interest (i.e. sodium azidfree neutralizing mouse monoclonal antibody against the EGFR (Oncogene Research Products, Cambridge, MA), mouse monoclonal IgG1 (DAKO, Glostrup, Denmark), MEK-1 inhibitor PD98059 (New England Biolabs Inc., Beverly, MA), or MEK-1/2 inhibitor U0126 (Calbiochem, San Diego, CA)) was added to four wells in each experimental group. Medium was renewed on Day 3, and on Day 6 cell growth was evaluated by a crystal violet colorimetric assay. In brief, the cells were incubated with a 0.5% crystalviolet-25% methanol solution for 10 min., before the absorbed dye was resuspended in a 0.1 M Sodium citrate-dihydrate-50% ethanol solution. The optical density was then measured for each well at wavelength 570 nm. Data represent the mean values ± SD of 3-4 wells.
Northern analysis
Cells in exponential growth phase were harvested by Trizol R Reagent and total RNA isolated according to the manufacturer's instruction (Life Technologies). Poly (A) + RNA was isolated with the Oligo (dT) 25 Dynabeads kit according to the manufacturer's manual (Dynal, Oslo, Norway). Poly (A) + RNA (2 µg) were denatured by dimethylsulfoxide/glyoxal, electrophoresed in a 1.0% agarose gel in 10 mM phosphate buffer (pH 7.0) and transferred to a nylon membrane NY 13N (Schleicher and Schuell, Dassel, Germany). An RNA ladder, 0.24-9.5 kb (BRL) was used as molecular size marker. Purified plasmid-derived DNA probes were labelled with [α-32 P]-dCTP (Amersham, Aylesbury, UK) using the Megaprime DNA labelling kit (Amersham) to a specific activity of 1 to 2 × 10 9 dpm/µg DNA, and the northern blots were hybridized according to the manufacturer's instructions using QuickHyb Hybridization Solution (Stratagene, La Jolla, CA). The blots were exposed to Kodak Biomax MR films at −80 • C. For quantification, the blots were exposed to a PhosphorImager TM (Molecular Dynamics) screen for 1-4 days before analysed using the ImageQuant TM software (Molecular Dynamics). Northern analyses were repeated twice using independent RNA preparations, respectively, and the results were reproducible.
Probes
Acidic ribosomal phosphoprotein P0 (36B4): 1.1 kb PstI fragment from 36B4 (ATCC 65917); c-erbB1 (EGFR): 2.4 kb ClaI fragment from pE7 (29) ; c-erbB2: 0.9 kb AccI to EcoRI fragment from pMAC117 [30] ; TGFα: 0.93 kb EcoRI fragment from pHTGF1-10-925 (ATCC 59951).
Western analysis
Cells for western analysis were harvested at about 80% confluency, using 0.5 ml RIPA (100 mM NaCl, 20 mM Trizma-Base, 1% Triton X-100; 0.5% sodium desoxycholate, 0.1% SDS, and 1 mM EDTA pH 8.0). Supernatants were collected after centrifugation at 10.000 × g for 15 min at 4 • C and frozen at −80 • C. Aliquots of cell lysate were denatured by boiling for 2 min in sample buffer (20% (v/v) glycerol; 4% (w/v) SDS; 10% (v/v) β-mercaptoethanol; 125 mM Tris-HCl (pH 6.8); 40 mM EDTA, and 0.05% (w/v) bromophenol blue) before electrophoresis in a 15% SDS-polyacrylamide gel. Proteins were transferred to an Immobilon-P membrane (Millipore, Bedford, MA) by electroblotting, and the membrane blocked over night at 4 • C in blocking buffer (5% w/v Non-fat dry milk, 0.2% Tween 20, 5% FCS in phosphate buffered saline (PBS)). The membrane was then incubated with primary antibody (1 h), followed by 1 h of incubation with peroxidase-conjugated secondary antibody before visualization using enhanced chemiluminiscence (ECL-Plus) detection system (Amersham).
Antibodies used for western analyses
Primary antibodies
Mouse monoclonal anti-human EGFR (Neomarkers, Union City, CA), mouse monoclonal anti-active human EGFR (Alexis Biochemicals, San Diego, CA), rabbit polyclonal anti-human MAP kinase 1/2 (Upstate Biotechnology, Lake Placid, NY), mouse monoclonal anti-active human MAP kinase 1/2 (Alexis Biochemicals), rabbit polyclonal anti-human ErbB2, amino acid (aa) 1169-1186, (Santa Cruz Biotechnology Inc, Santa Cruz, CA), rabbit polyclonal anti-human ErbB2, aa 1243-1255, (Neomarkers), rabbit polyclonal anti-active human ErbB2 (Upstate Biotechnology), and mouse monoclonal anti-human keratin no. 7 (K7) [31] .
Secondary antibodies
Peroxidase-conjugated rabbit anti-mouse immunoglobulins (DAKO) and peroxidase-conjugated goat anti-rabbit immunoglobulins (DAKO).
Results
Expression and E2-regulation of EGFR, TGFα, and c-erbB2 mRNA in F9 and S3B cells
The fact that cross-talk exists between the EGFR and ER pathways as well as the fact that the inverse relationship between EGFR and ER is disturbed in ERtransfectants, made us speculate that EGF probably is sufficient for maximal cell proliferation in our ERtransfected F9 cell line, and that the observed negative effect of E2 on cell proliferation in EGF-containing medium could be due to cross-talk between the EGFR and the ER pathways [26] . Previously, we have examined the transcriptional activity of ER in F9 cells by transient omission of EGF from the medium, resulting in an increased estrogenic response in F9 cells when analyzed by transfection with a reporter gene containing an estrogen response element (ERE). Moreover, omission of EGF from the growth medium resulted in the S3B cell line, which is dependent on E2 for growth [26] . Thus, it is possible that it is a change in the expression, activation and/or signalling via the EGFR, which results in the E2-mediated growth differences observed in F9 and S3B cells.
Previously we have shown that omission of EGF from the growth medium can result in overexpression of the EGFR [32] , thus, we examined the expression of EGFR mRNA in parental HMT-3522S1 cells as well as F9, S3B, and MCF-7 cells. As shown in Figure 1A , the mRNA expression level of EGFR was not significantly altered in S3B cells compared to F9 cells and parental HMT-3522S1 cells. No detectable level of EGFR mRNA was found in MCF-7 cells. The high level of EGFR mRNA found in F9 and S3B cells, derived from an ER-negative cell line, compared to non-detectable levels in MCF-7 cells, is in concordance with the observations of significantly higher levels of EGFR in ER-negative cell lines [24, 25] . Others have demonstrated that ligand-bound ER is capable of transiently up-regulating EGFR mRNA [3, 33] and in F9 cells, we did observe a transient E2-induced up-regulation of EGFR mRNA (data not shown). However, we did not detect any effect on EGFR mRNA expression by long-term E2 treatment (6 days), neither in F9 cells nor in S3B cells (Figure 1A) . Thus, we conclude that the growth regulatory difference observed between the two ER-transfected cell lines is not due to altered expression of EGFR mRNA.
Another mechanism for the E2-stimulated growth of S3B cells might be that the adaptation to an EGF-free environment could lead to constitutive upregulation of the EGFR ligand, TGFα. In F9 cells, we observed an up-regulation of TGFα mRNA in response to E2 as shown previously [21] . However, in S3B cells the TGFα mRNA level was 85-90% lower than in F9 cells and long-term treatment with E2 only results in a small, but insignificant 1.3-fold up-regulation of TGFα mRNA ( Figure 1B ). Although the TGFα mRNA level is considerably higher in F9 cells as compared to S3B cells, F9 cells require EGF supplementation for growth. Thus, we assume that the low TGFα mRNA level in E2-treated S3B cells is not the only cause for the growth stimulation by E2, thereby indicating that E2-regulated growth stimulation of S3B cells probably operates through a TGFα-independent pathway.
The possibility of an altered expression of the EGFR dimerization partner, c-erbB2, was also examined ( Figure 1C ). The level of c-erbB2 mRNA was 50-60% lower in S3B cells as compared to F9 cells. However, neither in F9 nor in S3B cells, did we observe down-regulation of c-erbB2 mRNA in response to long-term E2 treatment, but short-term treatment of F9 cells do result in a transient down-regulation of c-erbB2 mRNA (data not shown), which previously also has been observed in MCF-7 cells [34] . Therefore, we suggest that c-erbB2 mRNA expression is not involved in the altered growth response towards E2 in our ER-transfected cell lines. It seems more likely that the down-regulation of c-erbB2 mRNA in S3B cells is due to EGF-withdrawal from the cells.
Expression of EGFR protein in F9 and S3B cells
Our observation of low TGFα mRNA expression in S3B cells grown with E2 indicates a lack of sufficient growth stimulation via a TGFα signalling pathway. However, the possibility of an E2-mediated up-regulation of another EGFR ligand can not be Figure 1 . Expression levels of EGFR, TGFα mRNA, and c-erbB2 mRNA in F9, S3B, and MCF-7 cells. The parental cell line, HMT-3522S1 served as control. Two µg of polyA RNA isolated from HMT-3522S1, F9, S3B, and MCF-7 cells, cultured with or without 10 −9 M (MCF-7) or 10 −8 M E2 (F9 and S3B) for 6 days, were analysed by northern analysis. The northern blots were hybridized with specific probes against TGFα, EGFR, and c-erbB2. 36B4 (ribosomal phosphoprotein P0) served as internal control for RNA loading. Quantitative analysis of (A) EGFR mRNA levels, (B) TGFα mRNA levels, and (C) c-erbB2 mRNA levels is depicted in percent of control (HMT-3522S1) after normalization with 36B4. Results are presented as the mean ± SD (n = 3-4).
excluded. We therefore examined the expression of EGFR protein in F9 and S3B cells under different culture conditions. The culture conditions are based on the normal growth conditions for the cells that is S3B (+E2, −EGF) and F9 (−E2, +EGF). We also used a MCF-7 subline termed as MCF-7/S9 [28] , which is independent of the addition of growth factors and serum components for growth, but is growth stimulated by E2. This subline is a good model to compare with the S3B cell line, as both are grown under serum-free conditions and growth stimulated by E2. F9 cells grown in EGF-containing medium express a low level of total EGFR protein ( Figure 2A, lane 1) , and E2-treatment appears to have no effect on total EGFR protein expression ( Figure 2A, lanes 2-6) . A down-regulation of total EGFR protein is observed after 2 h of EGF treatment (Figure 2A , compare lane 7 with lane 12, and lane 13 with lane 17). This is in accordance with studies showing that EGF down-regulates its own receptor [35] , and with our own observation that the expression level of total EGFR protein is lower in F9 cells compared to S3B cells, when the cell lines are grown for 6 days in their respective basal media (data not shown). In S3B cells, no significant differences in the expression of total EGFR protein were observed in response to treatment with E2 for up to 2 h ( Figure 2B , lanes 1-6). In general, EGF-treatment of S3B cells for up to 2 h had little effect, if any on total EGFR. We used an antibody directed against the major autophosphoryla- (Figure 2A lanes 1-6) . S3B cells withdrawn from E2 for 48 h have a faint band of active EGFR ( Figure 2B lanes 1 and 13) , and active EGFR is hardly detectable in S3B cells treated for 5-120 min with E2 ( Figure 2B lanes 2-6) . Surprisingly, addition of EGF to S3B cells grown with E2 only resulted in a small barely visible increase in active EGFR protein between 10 and 60 min ( Figure 2B , lane 9-11), whereas EGF-treatment in medium without E2 results in significant amounts of active EGFR ( Figure 2B , lane 14 and 15). MCF-7/S9 cells neither express any detectable levels of EGFR protein nor active EGFR ( Figure 2C ).
Effect of E2 and EGF on MAP kinase expression and activity in F9 cells and S3B cells
As signal transduction through the EGFR activates a phosphorylation cascade involving the MAP kinases, we examined the expression of the MAP kinase Figure 2 . Total EGFR and active EGFR protein expression in F9, S3B, and MCF-7/S9 cells. Cell lysates from (A) F9 cells, (B) S3B cells, and (C) MCF-7/S9 were prepared from cell cultures treated with E2 or EGF during a 2 h interval. F9 and S3B cells were withdrawn from EGF and E2, respectively, for 48 h before treatment. Immunodetection of the indicated proteins was analyzed by western blot using 30 µg of protein on a 15% SDS-PAGE gel. EGFR protein was detected using mouse monoclonal anti-human EGFR or anti-active human EGFR (directed against the major autophosphorylation site, tyrosine (Y) 1173, of the EGFR) antibodies followed by incubation with polyclonal rabbit anti-mouse IgG peroxidase conjugated antibody. The immunocomplexes were visualized using the ECL Plus detection system. Keratin 7 (K7) served as a control for loading. All experiments were repeated 2-3 times, using separate cell lysate preparations, and the results were reproducible.
proteins (ERK1 and ERK2) in the F9, S3B, and MCF-7/S9 cell lines. Figure 3A and 3B show that both F9 cells and S3B cells express high amounts of total MAP kinase protein. MCF-7/S9 also expressed a high level of total MAP kinase protein ( Figure 3C ). The antibody used recognizes both ERK1 and ERK2 and as shown in Figure 3 activation of the MAP kinase by EGF results in an extra band, due to phosphorylation of MAP kinase protein, changing the migration rate during SDS-PAGE. This upshift is seen in F9 and S3B cells treated with EGF ( Figure 3A and 3B) and is a result of the EGFR pathway activating the MAP kinase by a phosphorylation cascade during the signal transduction [36] . We also used a MAP kinase Figure 3 . Active MAP kinase and total MAP kinase protein expression in F9, S3B, and MCF-7/S9 cells. Cell lysates from (A) F9 cells, (B) S3B cells, and (C) MCF-7/S9 were prepared from cell cultures treated with E2 or EGF during a 2 h interval. F9 and S3B cells were withdrawn from EGF and E2, respectively, for 48 h before treatment. Immunodetection of the indicated proteins was analyzed by western blot using 30 µg of protein on a 15% SDS-PAGE gel. MAP kinase protein was detected using rabbit anti-human MAP kinase or mouse anti-active human MAP kinase antibodies followed by incubation with polyclonal goat anti-rabbit or rabbit anti-mouse IgG peroxidase conjugated antibody. The immunocomplexes were visualized using the ECL Plus detection system. Keratin 7 (K7) served as a control for loading. All experiments were repeated 2-3 times, using separate cell lysate preparations, and the results were reproducible.
antibody specific for activated MAP kinase and as shown in Figure 3B it is clearly seen that short-term treatment of S3B cells with E2 neither involves MAP kinase activation nor changes in MAP kinase protein expression levels. Furthermore, we did not find any detectable MAP kinase activation upon 6 days E2-treatment of S3B cells ( Figure 3B, lane 7) , indicating that the E2-stimulated cell proliferation of S3B cells does not involve detectable MAP kinase activation. A marked increased in the expression of active MAP kinase protein was observed in response to EGF in F9 cells ( Figure 3A, lanes 8-12) as well as in S3B cells ( Figure 3B. lanes 14-18) . In both cell lines, the level of active MAP kinase protein was slightly decreased in response to EGF when the cells were concomitantly treated with E2 ( Figure 3A , lanes 14-17 and Figure 3B, lanes 8-12) . Interestingly, treatment of F9 cells, grown in their basal medium containing EGF, with E2 resulted in a decreased level of active MAP kinase protein in ( Figure 3A, lanes 1-6) . Moreover, the level of active MAP kinase protein is significantly lower in F9 cells which are grown in their basal medium containing EGF as compared to cells exposed to EGF after 48 h withdrawal of EGF under E2-free conditions ( Figure 3A, compare lanes 1-6 with 8-12) . The low level of active MAP kinase protein observed after 2 h of EGF-treatment could be the steady state level of active MAP kinase in EGF-containing medium, as it resembles the MAP kinase level observed in control cells cultured in EGF-containing medium for 6 days (compare Figure 3A lane 12 with lane 1). Thus, the low level of active MAP kinase protein appears to be associated with long-term treatment with EGF. EGF-treatment activates the MAP kinase in S3B cells cultured under estrogenic conditions ( Figure 3B , lanes 7-12) in spite of the fact that very low levels of active EGFR is observed ( Figure 2B, lanes 7-12) . Interestingly, neither short-term treatment of MCF-7/S9 cells with E2 or EGF activates the MAP kinase (Figure 3C) . MCF-7/S9 cells proliferate in the absence of serum components and other growth factors, but can be further growth stimulated by E2. Thus, we suggest that the E2-mediated cell proliferation of MCF-7/S9 cells acts independently of the MAP kinase.
Expression of ErbB2 protein in F9 and S3B cells
ErbB2 protein is a heterodimerization partner to EGFR involved in activation of the phosphorylation cascade, which activates MAP kinases [37] . The response and dimerization are highly dependent on ligand binding to EGFR. We examined the ErbB2 protein expression pattern of S3B cells and F9 cells, using antibodies raised against total ErbB2 protein and active ErbB2 protein, respectively. In both cell lines no significant changes in the expression level of total ErbB2 protein was observed in response to E2 or EGF treatment, neither alone nor in combination ( Figure 4A  and 4B ). The level of active ErbB2 protein is significantly lower in F9 cells treated continuously with EGF than in cells withdrawn from EGF 48 h before re-addition of EGF ( Figure 4A compare lane 1 with 7 and 13), suggesting a down-regulation of ErbB2 activity by continuous EGF treatment. Down-regulation of ErbB2 activity also occurs in F9 cells re-treated with EGF or EGF in combination with E2 for 2 h (Figure 4A , compare lane 7 with 12, and lane 13 and 17). S3B cells expressed active ErbB2 under all growth conditions examined, and it can not be excluded that active ErbB2 is involved in E2-mediated growth of S3B cells. The level of ErbB2 was slightly lower in S3B cells grown in basal medium containing E2, than in cells withdrawn from E2 for 48 h (figure 4B, compare lane 7 with lanes 1 and 13). The only significant reproducible regulation of active ErbB2 was a downregulation after 60-120 min of treatment with EGF ( Figure 4B, compare lane 13 with lanes 17 and 18) . In S3B cells, an extra band migrating at approximately 150 kDa during SDS-PAGE was observed. To elucidate the expression of the 150 kDa protein, we used an alternative antibody against ErbB2, which recognizes another part of ErbB2 (data not shown). This antibody only gave rise to a single band corresponding to the 185 kDa ErbB2 protein previously observed. Both antibodies recognize peptide fragments in the cytoplasmic (C-terminus) region of ErbB2 (aa 1169-1186 and aa 1243-1255, respectively, ErbB2 consists of 1255 aa) and it is possible that the 150 kDa band is due to a C-terminal truncated form of ErbB2. A 155 kDa protein has been detected by an ErbB2 antibody, and this protein was localized to the membranes of mitochondrial cristae of normal and malignant cells [38] . However, we can not exclude that the 150 kDa protein band observed by the ErbB2 antibody from Santa Cruz is due to a cross-reaction by the antibody. As the 150 kDa protein band is expressed independently on the treatment conditions, the band was not analyzed further.
Effect of neutralizing antibodies against the EGFR on the S3B cell growth
The detection of low levels of active EGFR protein as well as active ErbB2 protein in E2 treated S3B cells made us speculate that the E2-mediated growth stimulation of S3B cells could be due to an E2-mediated upregulation of an EGFR ligand. Therefore, we treated S3B cells with a neutralizing antibody raised against the EGFR. Mouse IgG was used as an internal control showing no non-specific growth inhibition in S3B cells. As shown in Figure 5 , S3B cell growth was inhibited approximately 50% in the presence of EGFR neutralizing antibody. No effect on S3B growth was observed when the cells were treated with control Immunodetection of the indicated proteins was analyzed by western blot using 30 µg of protein on a 15% SDS-PAGE gel. ErbB2 protein was detected using rabbit polyclonal anti-human ErbB2 or rabbit anti-active human ErbB2 followed by polyclonal goat anti-rabbit IgG peroxidase conjugated antibody. The immunocomplexes were visualized using the ECL Plus detection system. Keratin 7 (K7) served as a control for loading. All experiments were repeated 2-3 times, using separate cell lysate preparations, and the results were reproducible.
antibody, indicating that the EGFR is involved in S3B cell proliferation. Thus, these observations indicate that the E2-mediated growth stimulation of S3B cells involves an up-regulation of an EGFR ligand by E2. Surprisingly, EGF had no effect on S3B cell proliferation even though EGF still is capable of activating EGFR and MAP kinase in these cells ( Figure 2B and 3B, lanes [13] [14] [15] [16] [17] [18] . As the parental HMT-3522S1 cells are dependent upon EGF for growth these cells were used as a positive control for growth inhibition by the EGFR antibody. By using a concentration of 2 µg/ml EGFR antibody, cell growth was decreased by 30% in the presence of EGF, whereas removal of EGF gave rise to a 60% growth inhibition (data not shown), indicating that 2 µg/ml of EGFR antibody is not sufficient to totally avoid EGF binding to the EGFR as also seen for S3B cells in Figure 5 .
Effect of the MEK inhibitors, PD98059 and U0126, on S3B cell growth
To further investigate the E2-mediated growth mechanism of S3B cells, E2-stimulated S3B cells were treated with inhibitors of MEK, the upstream activator of MAP kinase. The MEK1 inhibitor PD98059 showed a dose-dependent inhibition of E2-mediated S3B cell growth, with a 30-40% inhibition at a concentration of 20 µM (Figure 6 ). In contrast, the MEK1 and MEK2 inhibitor, U0126 resulted in a 70-80% decrease in S3B cell growth. In S3B cells the IC 50 value of U0126 was determined to 4 µM, whereas the IC 50 value of PD98059 was determined to 30 µM (data not shown). These data indicate that MEK1 as well as MEK2 are involved in E2-mediated S3B cell growth. Figure 5 . The effect of neutralizing antibody against the EGFR on S3B cell growth. S3B cells were treated for 6 days with 2 µg/ml of EGFR neutralizing antibody in the absence (black bars) or presence of 1 ng/ml EGF (white bars) or 10 ng/ml EGF (grey bars) before the cell numbers were determined and the data depicted as percent of control (cells not treated with antibody (Ab)). IgG1 was used as an internal control. Results are presented as the mean ± SD (n = 3-4).
Discussion
Cultured human breast cancer cell lines expressing the ER have been utilized for studies on the mechanisms of estrogen action. However, normal breast epithelial cells expressing the ER have not been established in long term culture, but short-term cultures of normal breast epithelial cells respond to estrogen by enhanced cell growth [39] and microvilli formation [40] . Attempts to restore estrogen responsiveness of ER-negative cells by transfecting the ER cDNA into the cells have resulted in a negative or no growth response to E2 [23] . We speculated whether the negative growth response to E2 could be due to a disturbance of the inverse relationship between ER and EGFR in ER-transfected cell lines. Several investigations support this hypothesis, as it has been observed that EGFR-transfected MCF-7 cells have an increased proliferation rate, when E2 is omitted from the medium, and that addition of E2 to these EGFR overexpressing MCF-7 cells results in a selection of cells with a decreased EGFR level [41] . Moreover, van Agthoven et al. [42] found that EGFR-transfection of E2-stimulated, ER-positive ZR-75-1 breast cancer cells results in a significantly reduction of cell growth by the presence of EGF. In addition, transfection of ER-positive MCF-7 cells with antisense ER results in an increased EGFR mRNA expression [43] . Thus, it is likely that neither receptor may function optimally when expressed concomitantly. A survey of the literature available on ER-transfected cell lines, showed us that, generally, high levels of EGFR protein is detected in all these cell lines. We hypothesize that ER-transfected cell lines already have maximal growth Figure 6 . The effect of the MEK inhibitors, U0126 and PD98059, on S3B cell growth. S3B cells were treated for 6 days with varying concentrations of U0126 and PD98059 in the absence (white bars) and presence (gray bars) of 10 ng/ml EGF before the cell numbers were determined and the data depicted as percent of control (DMSO-treated cells). Results are presented as the mean ± SD (n = 3-4).
conditions, when EGF is present in the medium, and that addition of E2 to the cells only contributes negatively to the growth pattern. Previously we have stably transfected the ER-negative non-tumorigenic human mammary epithelial cell line, HMT-3522S1, [20] with the human estrogen receptor cDNA [21] . The ERpositive established cell line, HMT-3522F9, is growth inhibited by estrogen, and by omitting EGF from the growth medium, we have been able to establish an ER-transfectant cell line, HMT-3522F9/S3B, dependent on E2 for growth [26] . In the present study, we try to elucidate mechanism(s) involved in the altered E2-mediated growth response in F9 cells compared to S3B cells.
Previously we have observed an increase in ER transcriptional activity from 5-to 8-fold in response to E2 by omitting EGF from the medium of F9 cells [26] . Thus, it is highly possible that it is EGF which dominates the growth potential of F9 cells, and thereby no positive effect of E2 can be contributed to F9 cell proliferation. In fact, E2 has a negative influence on F9 cell growth and we assume that E2 acts in co-operation with EGF to provide a negative effect on F9 cell proliferation. Conversion of EGF-induced proliferation of F9 cells to E2-stimulated growth of S3B cells, caused by adaptation of F9 cells to EGF-free conditions, could be the result of alterations in ER/EGFR cross-talk.
The EGFR ligand, TGFα, was reduced with 85-90% at the mRNA expression level in S3B cells compared to F9 cells. The huge decrease in the TGFα mRNA expression level in S3B cells compared to the level observed in F9 cells possibly originates from withdrawal of EGF from the medium during adaptation of the S3B cell line, as it has been observed that EGF can up-regulate the TGFα mRNA expression level [44] . E2 induces a 2.7-fold increase in TGFα mRNA expression in F9 cells, whereas no significant increase was observed in S3B cells in response to E2. Thus, we assume that TGFα is not involved in the E2-mediated cell proliferation observed in S3B cells. We did not find any significant changes in the regulation of the c-erbB2 mRNA level in response to longterm E2-treatment in F9 or in S3B cells, respectively.
Short-term treatment of F9 cells does result in a transient down-regulation of c-erbB2 mRNA (data not shown) as previously observed in MCF-7 cells [34] . The level of c-erbB2 mRNA was 50-60% lower in S3B cells compared to F9 cells, and as ErbB2 is the preferred heterodimerization partner for the EGFR [37] , down-regulation of the c-erbB2 mRNA level could be due to EGF-withdrawal, thereby preventing excessive production of c-erbB2 mRNA. In other words, a mechanism where transcription of c-erbB2 mRNA automatically is down-regulated when no active heterodimerization partner (i.e. EGFR) is available could be involved. This is in contrast to findings where EGF has no influence on c-erbB2 mRNA expression in T47D, ZR75.1 and SKBR3 breast cancer cell lines [45] , and no differences were observed in total ErbB2 protein expression level between F9 and S3B cells. The level of active ErbB2 protein was found to be lower in F9 cells treated continuously with EGF than in cells withdrawn from EGF 48 h before re-addition, indicating that ErbB2 activity is down-regulated by EGF, and thereby suggesting that EGF signalling probably occurs by heterodimerization between the EGFR and ErbB2 protein in F9 as well as S3B cells. EGF treatment of HC11 mouse mammary cells has been found to result in down-regulation of ErbB2 by increasing phosphorylation and accelerating the rate of ErbB2 internalization and degradation [46] , and in T47D breast cancer cells EGF down-regulates ErbB2 at a post-translational level [47] . No increased activation of ErbB2 was observed in response to EGF in F9 and S3B cells, but signalling through the EGFR could be involved in the down-regulation of the basal level of active ErbB2 protein observed in the presence of EGF. No significant change in total ErbB2 protein was observed in response to E2 or EGF in S3B cells. Interestingly, active ErbB2 protein is present in S3B cells grown in the absence and presence of E2.
Transient E2-induced up-regulation of EGFR mRNA, which has been observed in MCF-7 [3] , was also seen in F9 cells (data not shown). However, long-term treatment with E2 in F9 and S3B cells, respectively, showed no change in the EGFR mRNA expression level, and the levels of EGFR mRNAs were not significantly different in the two cell lines. Thus, altered EGFR mRNA expression does not seem to be the reason for the growth regulatory differences between the two cell lines. However, the level of total EGFR protein is significantly increased in S3B cells compared to F9 cells when the cell lines are grown in their basal media, whereas no significant changes was seen at the mRNA level. This indicates a different post-translational regulation of the EGFR between the cell lines, which might be due to the fact that F9 cell in contrast to S3B cells are grown in EGF-containing medium. In NIH 3T3 cells, EGF negatively regulates the expression of its own receptor by a negative feedback mechanism involving internalization and degradation of the receptor [35] , and it seems plausible that a negative feedback mechanism also exists in F9 cells, explaining the reduced level of EGFR protein in these cells. In F9 as well as S3B cells, transient activation of EGFR protein was observed in response to EGF. In addition, the very low levels of active EGFR protein detected in E2-treated S3B cells, suggest that the E2-mediated growth stimulation of S3B cells could require activation of the EGFR, for instance by the induction of an ErbB family ligand. The total MAP kinase protein level is very high in F9, S3B, and MCF-7/S9 cells. However, as activation of the MAP kinase normally is transient and happens within seconds, it seems reasonable that this protein is stored in the cells ready for activation. EGF increases MAP kinase activity in F9 cells as well as in S3B cells, indicating signalling of EGF through the EGFR/MAP kinase signalling pathway. In S3B cells, EGF activates the MAP kinase both in the absence and presence of E2, although the level is significantly reduced under estrogenic conditions. Surprisingly, the levels of active EGFR induced by EGF was nearly undetectable in S3B cells in the presence of E2. However, we assume that the reduced EGFR activity may explain the reduced MAP kinase activity. MAP kinase activity is present in EGF-treated F9 cells, and addition of E2 decreases the level of active MAP kinase. Treatment of F9 cells with E2 and EGF after withdrawal of EGF for 48 h to allow re-expression of EGFR, results in a slightly decreased response to EGF at the level of active MAP kinase protein compared to cells treated with EGF alone. Thus, the fact that E2 inhibits F9 cell growth and decreases the level of MAP kinase activity, indicates a MAP kinase dependent growth inhibitory mechanism of E2. These results are in accordance with the observations of an increased MAP kinase activity in response to E2-stimulated growth in several MCF-7 cell lines [14] [15] [16] 48] . However, it should be mentioned that the MCF-7/S9 subline used in this study does not express detectable levels of active MAP kinase, which is in contrast to the studies referred to above. Surprisingly, no E2-mediated increase of MAP kinase activity is observed in S3B cells even though low amounts of active EGFR as well as active ErbB2 protein was detected, suggesting the use of an alternative growth signalling pathway. A neutralizing antibody against the EGFR inhibits S3B cell growth approximately 50%. Moreover, the MEK-1/2 inhibitor, U0126, resulted in a 70-80% decrease in S3B cell growth, whereas the MEK-1 inhibitor, PD98059, only gave rise to a 30-40% decrease of S3B cell growth. The inhibitor concentrations used are within the range known to give specific effects [49] , thus, these data suggest that MEK-1 and MEK-2 are involved in E2 stimulation of S3B cell growth. This seems puzzling as the function of MEK-1/2 is to activate the ERK1/ERK2 MAP kinases [50] . However, it has been observed that the MEK kinase 1 (MEKK1) phosphorylates MEK-1 and MEK-2 without causing activation of MAP kinase [51] . Therefore, it is possible that EGFR-and/or ErbB2-mediated activation of MEK can signal through a MAP kinase independent mechanism. Moreover, we can not exclude the involvement of ErbB3 and/or ErbB4 in E2-mediated growth stimulation of S3B cells. The observed undetectable level of active MAP kinase does not totally exclude involvement of active MAP kinase, but compared to the level of MAP kinase activation observed upon EGF treatment of S3B cells, we believe that MAP kinase activation upon E2-treatment is negligible. These data suggest that signalling through MAP kinase is not the major pathway in E2-mediated growth stimulation of S3B cells.
F9 cells activate the EGFR signalling pathway in response to EGF-induced growth and E2 contributes negatively to the EGF-stimulated growth by decreasing signalling via the EGFR/MAP kinase signalling pathway, whereas the E2-induced growth of S3B cells does not involve activation of MAP kinase. These results indicate that the presence of EGF and E2 concurrently could result in inhibition of the EGFR/MAP kinase pathway. Inhibition of the EGFR signalling pathway has been observed in fibroblasts and in murine cells, where a negative feedback mechanisms involves MAP kinases and protein kinase phosphatases [52] . Direct serine phosphorylation of the EGF receptor by the MAP kinase has been found to decrease EGF receptor tyrosine phosphorylation through a vanadate-sensitive pathway involving activation of a tyrosine phosphatase [52] . Moreover, protein tyrosine phosphatases like SHP-1 and SHP-2 interacts with the SH-2 domains of the EGFR, and thereby attenuate receptor signalling by dephosphorylation of phosphotyrosines [53, 54] . Hence, it is possible that the low level of active MAP kinase and EGFR activity in F9 cells continuously grown in EGF and treated with E2 involves induction and/or activation of tyrosine kinase phosphatases, and thereby leading to growth inhibition. Furthermore, it should be mentioned that the effects of E2 on the EGFR/MAP kinase signalling pathway are rapid effects, which happen within minutes. Recent studies have shown that the nongenomic actions of E2 can be mediated through the plasma membrane [55, 56] , and it appears that many of the rapid effects is a result of E2-mediated modulation of G-coupled receptors, leading to a variety of signal transduction events [57] . Moreover, recently it was shown that the EGFR has a role in G-coupled signalling leading to Ras/MAP-kinase activation, and the authors suggest a ligand-independent mechanism of EGFR activation through intracellular cross-talk [58] . Transient transfection of the ER into CHO cells showed the expression of both membrane and nuclear ERs, where the membrane receptors were capable of signalling via G-coupled receptors [59] . Thus, crosstalk between the EGFR and ER could occur at the level of G-coupled receptors, and we can not exclude that F9 and S3B cells express membrane ERs, and thereby signal via G-coupled receptors. Furthermore, the E2-ER complex has been found to stimulate c-src kinase activity within minutes [14] , suggesting that the c-src kinase could be a part of the signalling events mediated by the ER.
It should be noted that S3B cells do grow via an ER-mediated mechanism, as the cells are growth inhibited by ICI 182.780 [26] . Furthermore, the cells express progesterone receptor protein in response to E2, indicating that active ER is present in these cells [26] . Thus, our observations are in agreement with our hypothesis 'that the negative growth response towards E2 often observed in ER-transfected cell lines could be due to disturbance of the inverse correlation between ER and EGFR', as these cells already have maximal growth conditions, when EGF is present in the medium. In fact, we do find that both receptors only function optimally when expressed alone. Moreover, this hypothesis appears to be in accordance with several observations showing that ER-negative cells are the proliferative cells in normal, human breast epithelium [60] . Thus, in conclusion we propose an E2-mediated growth stimulatory mechanism of S3B cells, which depends on an EGFR/ErbB2 signalling pathway, where signalling via the MAP kinase is not the major pathway. We furthermore suggest the E2-mediated growth inhibition of F9 cells to be due to inhibition of the EGF-induced MAP kinase signalling pathway. In fact we do find that E2-mediated inhibition of EGF-induced signalling is observed in F9 as well as S3B cells, suggesting a more general mechanism of action in cells concomitantly expressing ER and EGFR. Finally, it is possible that the action of estrogens in normal breast epithelium also is modulated by the EGFR in vivo.
